The Effect of Statins on Dementia Risk in Familial Hypercholesterolemia
Researchers sought to examine whether individuals with familial hypercholesterolemia are at a heightened risk for dementia and whether statin use is tied to dementia risk.
Familial Hypercholesterolemia
Unique Risks in People With Familial Hypercholesterolemia and COVID-19
People with familial hypercholesterolemia with COVID-19 risk endothelial dysfunction. Therapy should continue during the course of the virus.
Repatha Approved for Younger Patients with HeFH and HoFH
The approval of Repatha was also expanded to include patients 10 years of age and older with HoFH.
Managing the Interplay of Familial Hypercholesterolemia and COVID-19
About 90% of those with familial hypercholesterolemia have not been diagnosed or treated for it, leaving them more vulnerable for COVID-19 infection and its complications.
Inclisiran Safe, Effective in Reducing LDL-C in Patients With Familial Hypercholesterolemia or ASCVD
Researchers conducted a patient-level pooled analysis from phase 3 trials of inclisiran in patients with familial hypercholesterolemia or ASCVD.
Alirocumab Approved for Homozygous Familial Hypercholesterolemia
The approval was based on data from the phase 3 ODYSSEY HoFH trial, which evaluated Praluent in 69 adults with HoFH who were on other LDL-C-lowering therapies.
Lipoprotein Apheresis Treatment for Hyperlipoproteinemia and Familial Hypercholesterolemia
Lipoprotein apheresis was associated with reduced concentrations of LDL-C and Lp(a) in patients with hyperlipoproteinemia (a) and FH on a maximally tolerated lipid-lowering regimen.
Evinacumab Lowers LDL Cholesterol in Refractory Hypercholesterolemia
In this phase 2 trial, patients with hypercholesterolemia and clinical atherosclerotic cardiovascular disease were recruited from 85 sites across 20 countries.
LDL-C Polygenic Risk Score and ASCVD in Monogenic Familial Hypercholesterolemia
Elevated LDL-C polygenic scores associated with higher LDL-C levels and increased risk for ASCVD in patients with monogenic familial hypercholesterolemia.
Dyslipidemia Medication as Thrombosis Prophylaxis in Patients With COVID-19 and FH
The treatment of patients with familial hypercholesterolemia and COVID-19 with dyslipidemia medications may prevent the occurrence of thrombotic events.
- Loading...
Loading...
Next post in Cardiovascular and Metabolic Disorders
Loading... 
Loading...